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ABSTRACT
Cytokines are considered important factors in the modulation of various immune responses.
Among them, interleukin (IL)-21 is one of the major immune modulators, adjusting various immune
responses by affecting various immune cells. It has been suggested that IL-21 may enhance
autoimmunity through different mechanisms, such as development and activation of helper T (TH)-
17 and follicular helper T (TFH) cells, activation of natural killer (NK) cells, enhancing B-cell
differentiation and antibody secretion and suppression of regulatory T (Treg) cells. Moreover, IL-21
has also been suggested to be an inducer of autoimmunity when following treatment of MS
patients with some therapeutics such as alemtuzumab. This review will seek to clarify the precise
role of IL-21/IL-21R in the pathogenesis of MS and, in its animal model, experimental autoimmune
encephalomyelitis (EAE).
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Introduction
Cytokines play an important role in the modulation of
several immune and non-immune related processes.
Moreover, some cytokines have critical roles in the
induction, initiation, progression and attenuation of a
variety of diseases (Ghalamfarsa et al. 2013; Tangye
2015). Thus, it seems that identification of the precise
mechanism(s) by which cytokines modulate disease
status may help design new therapeutic methods of
treatment.
Interleukin-21 (IL-21), a member of the common
-chain cytokine family, has attracted much attention
among investigators because of its complex structure and
multi-functionality. Several cell types, such as helper T
(TH)-17, follicular helper T (TFH), Th2 and natural killer
T (NKT) cells, can produce IL-21. Moreover, a wide
variety of immune and non-immune cells express the
IL-21 receptor (IL-21R) on their surface (Nurieva et al.
2007; Zhou et al. 2007; King et al. 2008; Suto et al. 2008).
Thus, it seems that IL-21 may play a critical role in the
immuno-pathogenesis of several types of cancers and
autoimmune diseases.
Multiple sclerosis (MS), a central nervous system
(CNS)-related chronic inflammatory demyelinating dis-
ease, is characterized by re-occurring episodes of
demyelination and axonal lesion induced by TH (par-
ticularly TH1 and TH17) cells, macrophages and soluble
inflammatory mediators (Jadidi-Niaragh and Mirshafiey
2010, 2011b, 2011c). There is also evidence implying the
role of other immune cells such as TFH, NK and B-cells
in the immunopathogenesis of MS (Chanvillard et al.
2013; Plantone et al. 2013; Romme Christensen et al.
2013; Haugen et al. 2014). Although the precise etiology
of MS is unknown, it has been is suggested that genetic
and environmental factors have great influences on
the onset and progression of MS (Mirshafiey and Jadidi-
Niaragh 2010a, b).
Increased levels of IL-21 have been observed during
the progression of several auto-immune diseases; this
implies a pathologic function for this cytokine in
autoimmunity (Zanin-Zhorov et al. 2014). Moreover, it
has been reported that IL-21 acts as a pro-inflammatory
agent during MS progression and so it has been
suggested that IL-21 may promote disease advancement
(Vollmer et al. 2005). Since TH17 cells play an important
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role in the neuro-inflammatory process of MS, with
regards to the stimulatory effect of IL-21 on development
and expansion of TH17 cells, it has been proposed that
IL-21 and IL-21R may be considered key targets in the
treatment of MS. This review intends to discuss the
precise roles for IL-21/IL-21R in the immunopathogen-
esis/treatment of MS and in its animal model, experi-
mental autoimmune encephalomyelitis (EAE).
Multiple sclerosis
MS is a complex heterogenic autoimmune disease of the
CNS in which the myelin sheaths of the neurons are
relatively destroyed by self-reactive immune responses
(Mirshafiey et al. 2014). MS patients may express several
manifestations such as paresthesia, diplopia, visual
impairment, numbness or weakness of the limbs, bowel
or bladder dysfunction, spasticity, ataxia, fatigue and
altered mental functions (Gaby 2013). Although the
precise etiology of MS is unknown, genetic and envir-
onmental factors play key roles in its etiology (Hoglund
and Maghazachi 2014). There are four main phenotypes
of MS including relapsing remitting (RR), primary
progressive (PP), secondary progressive (SP) and pro-
gressive relapsing (PR) (Gaby 2013). It seems that
destruction of the blood–brain barrier (BBB) and
migration of autoreactive T-cells from the blood to the
CNS are the main processes involved in the development
of MS (Cheng and Chen 2014). Following the breakdown
of the BBB (due to several triggers such as oxidative
stress), peripheral activated lymphocytes infiltrate the
CNS and induce local immune responses, ultimately
destroying the myelin and even the axons themselves
(Ortiz et al. 2014). Injured cells in the BBB secrete
various inflammatory cytokines and chemokines that
play an important role in the recruitment of inflamma-
tory cells to the CNS (Cheng and Chen 2014). It seems
that autoreactive lymphocytes are initially activated in
the systemic lymphoid organs by various mechanisms
like molecular mimicry and bystander activation.
Subsequently, they transmigrate to the CNS where they
are re-activated following the encounter of their specific
antigen, which eventually leads to demyelination and
axonal damage (Hartung et al. 2014).
Although autoreactive T (particularly TH1 and TH17)-
cells are the main players in the immunopathogenesis of
MS, innate immune responses are also involved in its
initiation and progression (Roozbeh et al. 2014). In
addition to TH cells, CD8
+ T-cells also contribute to the
development of the disease and clonally expanded CD8+
T-cells are observed within the MS lesions (Denic et al.
2013). The invariant natural killer T (iNKT)-cells are
another lymphocyte sub-type which can secrete various
cytokines (such as interferon [IFN]-), interleukin
(IL)-10, IL-4) and may be involved in disease progres-
sion (Roozbeh et al. 2014). Regulatory T (Treg) cells play
an important role in the maintenance of self-tolerance in
the immune system. It has been reported that, although
the frequency of Treg cells is intact in MS patients,
their functionality is rather perturbed (Jadidi-Niaragh
and Mirshafiey 2011a). A skewed balance between Treg
and TH17 cells during MS progression has also been
demonstrated (Jadidi-Niaragh and Mirshafiey 2012).
In addition to T-cells, B-cells are also supposed to
have a critical effect in the immunopathogenesis of MS.
B-cells secrete various antibodies and cytokines which
can enhance disease furtherance. They can also act as
antigen presenting cells for T-cells. Moreover, identifi-
cation of regulatory B-cells with anti-inflammatory
function further complicates the identification of the
precise role of B-cells in MS development (Krumbholz
and Meinl 2014).
Immunobiology of IL-21
IL-21 is a member of the Class I cytokine family, which
includes IL-2, -4, -7, -9 and -15 (Spolski and Leonard
2008). The IL-21R exhibits homology with the -chain
of IL-2/IL-15Rs and constitutes a complex with the
common -chain (Collins et al. 2003; Parrish-Novak
et al. 2000). Several types of immune cells, such as
activated TH, NKT, TFH and TH17 cells, can produce
IL-21 (Parrish-Novak et al. 2000; Mehta et al. 2004;
Leonard and Spolski 2005; Spolski and Leonard 2008).
This cytokine regulates the differentiation and function
of various immune cells. Interaction of IL-21 with its
receptor leads to regulation of activation, proliferation
and survival of both TH and B-cells. It can also inhibit
the differentiation and function of inducible Treg cells
(Monteleone et al. 2009). Moreover, IL-21 plays an
important role in the development of TFH (Shekhar and
Yang 2012), B-cell somatic hypermutation and immuno-
globulin class switching (Eto et al. 2011), TH2 cell
function (Pesce et al. 2006), expansion and activity of
CD8+ T-cells (Zeng et al. 2005), cytotoxic activity of NK
cells (Strengell et al. 2003) and the differentiation and
function of NKT cells (Smyth et al. 2005; Coquet et al.
2007). It is reported that, while the IL-21 enhances the
cytotoxic function and IFN secretion in murine-derived
activated NK cells, it inhibits IL-15-mediated expansion
of resting NK cells (Kasaian et al. 2002). IL-21 also
promotes the terminal differentiation of mouse NK cells
(Brady et al. 2004; Li et al. 2015). Further, IL-21
enhances the proliferation, IFN generation and cyto-
toxic activity of CD8+ effector T-cells in allogeneic
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mixed-lymphocyte responses (MLR) (Kasaian et al.,
2002).
IL-21 can potently affect the B-cell proliferation,
survival, differentiation and immuno-globulin responses
(Ghalamfarsa et al. 2013, 2015; Spolski and Leonard
2014) While the IL-21 induces apoptosis of B-cells, it
enhances IL-4 mediated B-cell proliferation and differ-
entiation toward memory or plasma cells (Ettinger et al.
2005). These contradictory functions of IL-21 on B-cells
depend on the interplay with co-stimulatory signals and
the developmental stage of B-cells (Konforte et al. 2009).
IL-21 also stimulates antibody production and, thereby,
enhances host defense against various malignances and
infectious diseases (Ettinger et al. 2008).
IL-21 also increases resistance of effector T-cells
against the suppressive function of Treg cells (Peluso
et al. 2007). It can also inhibit granulocyte–macrophage
colony-stimulating factor (GM-CSF)-mediated dendritic
cell (DC) maturation. Thus, IL-21 shifts DC toward
immature phenotype, which inhibits T-cell responses
and induces Treg cells (Brandt et al. 2003). In addition,
IL-21 decreases the expression of MHC Class II, CD80,
CD86 and CCR7 on the surface of DC and inhibits the
secretion of IL-6, IL-12, IL-1 and tumor necrosis factor
(TNF)- cytokines by DC (Brandt et al. 2003; Strengell
et al. 2006). It can also induce apoptosis of conventional
DC in a STAT3- and BIM-dependent manner
(Wan et al. 2013).
TH17 cells generate IL-21 in a STAT3-dependent
manner and IL-21 induces expression of RAR-related
orphan receptor -t (RORt), IL-17A and IL-17F in a
positive autocrine loop that leads to expansion of TH17
cells (Wei et al. 2007). IL-21 can promote differentiation
of TH17 cells, even in the absence of IL-6 (Deenick and
Tangye 2007). Moreover, IL-21 skews the balance
between TH17 and Treg cells toward TH17 cells through
STAT3 and RORt transcription factors (Deenick and
Tangye 2007; Korn et al. 2007; Nurieva et al. 2007). It
was also demonstrated that the frequency of TH17 cells
was significantly reduced when the IL-21/IL-21R signal-
ing was blocked (Deenick and Tangye 2007; Korn et al.
2007; Nurieva et al. 2007). Secretion of IL-21 and IL-17
from T-cells can be controlled via ROCK2 through
STAT3, IRF-4 and RORt. It is reported that inhibition
of ROCK2 increases the suppressive function of Treg cells
via up-regulation of STAT5 phosphorylation. Thus, the
use of ROCK2 antagonist shifts the TH17/Treg balance
toward the Treg phenotype (Zanin-Zhorov et al. 2014).
TFH cells express B-cell CLL/lymphoma-6 (BCL6)
transcription factor and can produce high levels of IL-21
(Chtanova et al. 2004). IL-21 enhances the secretion of
TNF by conventional T-cells, which leads to up-
regulation of CXCL9 on DC in the draining lymph nodes
and facilitates TFH differentiation (Yoo and Braciale
2014). As IL-21 affects the differentiation, function and
survival of a wide variety of immune cells, it may be
considered as a worthy target for treatment of several
diseases.
IL-21 and IL-21R in CNS-related disorders
There is evidence implying IL-21 modulates the self-
reactive immune responses in various CNS-related
autoimmune diseases (Petrelli et al. 2011; Yoshizaki
et al. 2012; Linhares et al. 2013; Liu et al., 2015). Geri
et al. (2011) have reported that IL-21 promotes inflam-
matory lesions in Behçet disease (BD) through the
expansion of TH17 and suppression of Treg cells. BD is
chronic systemic inflammatory disease that can also
involve the CNS. They showed that, while the serum of
patients with active BD enhances the production of IL-17
in purified CD4+ T-cells of healthy donors, it reduces the
expression of forkhead box protein 3 (FoxP3) in vitro.
Moreover, they could detect IL-21- and IL-17A-produ-
cing T-cells within cerebrospinal fluid, brain paren-
chyma inflammatory infiltrates and intra-cerebral blood
vessels of patients with active BD with CNS involvement.
Further, treatment of isolated CD4+ T-cells with IL-21
led to the up-regulation of TH17 and TH1 and down-
regulation of Treg cells. On the other hand, blocking
IL-21 via an IL-21R-Fc restored the TH17 and Treg cell
balance in BD patients by suppressing IL-17A produc-
tion and increasing FoxP3 expression (Geri et al. 2011).
Thus, it was proposed that IL-21 enhanced disease
progression, in part, through promotion of inflammatory
responses by expansion of TH17 cells and also interfered
with self-tolerance by down-regulation of Treg cells.
In another study, Linhares et al. (2013) investigated the
function of T-cells in patients with neuromyelitis optica
(NMO), which is a type of CNS-related autoimmune
disease. Those authors showed that, while TH1 cytokines
were decreased in cultured T-cells isolated from NMO
patients, TH17 and related cytokines (i.e. IL-23 and IL-6)
were significantly increased. Moreover, polyclonal stimu-
lation of CD4+ T-cells led to the secretion of IL-21 and IL-
6 that was positively correlated to neurological disability
and was resistant to glucocorticoid inhibition in NMO
patients. Based on that previous study, it seemed that the
presence of a positive autocrine loop between TH17 and
IL-21 might play a pivotal role in the immunopathogen-
esis of CNS-related autoimmunity.
There is also evidence which indicates an important
role of IL-21 in CD8+ T-cell survival in the CNS during
acute mortal JHMV and West Nile (WNV) viral
infections (Stohlman et al. 1998; Janssen et al. 2005;
Sitati and Diamond 2006; Fro¨hlich et al. 2009; Barker
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et al. 2010). It is suggested that CD4+ T-cells are the
main source of IL-21 in the CNS, since it was observed
that its mRNA level was significantly reduced in the CNS
of CD4+ T-cell-depleted mice (Phares et al. 2011). It is
also suggested that IL-21 producing CD4+ T-cells
promote the peripheral activation of CD8+ T-cells and
increase their antiviral function within the CNS (Phares
et al. 2012). Moreover, IL-21R deficiency was associated
with the down-regulation of IFN and IL-10 in CNS-
derived CD4+ T-cells and disturbed peripheral B-cell
activation and impaired CNS humoral responses (Phares
et al. 2013). Thus, IL-21 secreting T-cells may enhance
antibody production by B-cells, which may promote
autoimmune responses (Metcalf et al. 2013). Similar
results regarding the stimulatory and pathologic effects
of IL-21, on both T- and B-cells in the CNS, have been
reached using toxoplasma gondii-infected IL-21-deficient
mice (Stumhofer et al. 2013).
An increased frequency of IL-21- and IL-9-producing
CD4+ T-cells has also been noted in Alzheimer’s disease
(Saresella et al. 2011). The extent of brain atrophy was
also highly correlated with IL-21 producing CD4+ T-cells
(Baglio et al. 2013). Moreover, using IL-21R-deficient
mice with experimental autoimmune uveitis, it was
demonstrated that blocking IL-21 signaling could lead to
attenuation of CNS auto-inflammatory diseases (Wang
et al. 2011b). It was also reported that IL-21 was
increased in the injured mouse brain after cerebral
ischemia. Moreover, IL-21-deficient mice exhibited
smaller infarcts, better neurological function and
decreased lymphocyte infiltration into the brain. The
brain infiltrated CD4+ T-cells were the main source of
IL-21. Administration of IL-21 receptor Fc fusion protein
to these mice protected them from re-perfusion injury.
Further, IL-21 was identified as a mediator of brain
injury in post-mortem human brain tissue, since IL-21
was detected in perivascular CD4+ T-cells in the area
surrounding acute stroke lesions (Clarkson et al. 2014).
Lastly, Daga et al. (2007) was able to successfully
eradicate glioblastoma (a tumor of the CNS) in mice
through local delivery of IL-21 by IL-21 gene-transduced
cells or using recombinant IL-21. These investigators
showed that IL-21 exerted its anti-tumor effects mainly
through the activation of anti-tumor antibody-secreting
B-cells. That study aimed to prove the ability of IL-21 in
the activation of B-cells in the CNS, which has been little
researched until now.
Thus, it seems IL-21 is an important factor for the
modulation of immune responses and inflammatory
reaction in the CNS. In some disease such as BD and
brain stroke, inhibition of IL-21 led to disease attenu-
ation. On the other hand, IL-21 protected hosts against
viral encephalitis and glioblastoma through stimulation
of anti-viral and anti-tumor immune responses. The
above-mentioned studies demonstrated that IL-21
exerted its effects, in part, through effects on the
expansion of TH17 and TH1 cells, suppression of Treg
cells and modulation of humoral immune responses.
The skewed balance between TH17 and Treg cells has
frequently been noted in various cancers and auto-
immune diseases and known to be an important factor in
the immuno-pathogenesis of several diseases (Gol-Ara
et al. 2012; Azizi et al. 2013; Jadidi-Niaragh and
Mirshafiey 2012; Jadidi-Niaragh et al. 2013a, b, c).
Thus, it is obvious to us that IL-21 was an essential
immune factor for the modulation of neuro-inflamma-
tory reactions in CNS-related disorders.
Expression of IL-21 and IL-21R in multiple
sclerosis
It has been suggested that the expression of IL-21/IL-
21R has high associations with different autoimmune
diseases (Collins et al. 2003; Vollmer et al. 2005).
Moreover, the polymorphism of IL-21 showed a high
association rate with the susceptibility to autoimmune
disease in Caucasians (Liu et al., 2015). Consistently,
the gene and surface expressions of IL-21 and IL-21R
were significantly increased in the CD4+ T-cells from
patients with progressive MS (Romme Christensen et al.
2013). On the other hand, it has been reported that IL-
21 was only over-expressed on infiltrating CD4+ T-cells
in the acute and chronic white matter of MS lesions,
whereas IL-21R was mainly expressed on CD4, CD19
and CD8 lymphocytes, but not MHC II-expressing
macrophages/microglia. Both of the IL-21 and IL-21R
were also expressed in neurons in the cortical area
(Tzartos et al. 2011). There are similar results regarding
the association of IL-21R gene polymorphism and MS
disease (Nohra et al. 2010). Further, increased expres-
sion of IL-21 mRNA was detected during MS relapses
(Tegla et al. 2013). Oddly, there was no significant
change in the cerebrospinal fluid (CSF) concentration
of IL-21 in MS patients (Wu et al. 2012). In addition, it
was reported that IL-21 was not considered a major
risk factor for MS in Spanish and Swedish populations
(Fedetz et al. 2009; Linden et al. 2011). Another study
demonstrated there were no significant differences in
serum levels of IL-21 between MS patients and normal
subjects (Wang et al. 2011a). These discrepancies (as
shown in Table 1) may be due in part to the different
sample sources, assessment techniques and sample
sizes. It seems further studies are required to clarify
precise relations between expression of IL-21/IL-21R
and MS (Fedetz et al. 2009).
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IL-21/IL-21R in EAE
Several studies have been demonstrated that prove
IL-21/IL-21R can exacerbate EAE in part through the
development of TH17 cells (Table 2). Consistently, IL-21
or IL-21R deficient mice showed attenuated EAE that
was associated with a significant reduction of TH17
(Korn et al. 2007; Nurieva et al. 2007; Spolski and
Leonard 2008) and expansion of Treg cells (Nurieva et al.
2007). Administration of IL-21 to mice before EAE
induction was also associated with an increase in TH17
and a decrease in Treg cells (Korn et al. 2007). Treatment
of proteo-lipid protein (PLP)-induced EAE mice with
salmonella-CFA/IIC was also associated with disease
attenuation and reduction of IL-17 and IL-21 cytokine
levels, which implies the pathologic role of IL-21 in EAE
(Ochoa-Reparaz et al. 2008). Similar results were
observed when EAE mice were treated with DNA-
carrying vaccines (Andersson et al. 2008). Regarding the
studies mentioned above, it seems that IL-21/IL-21R
could be considered as a pathologic axis in EAE. Thus,
some investigators have tried to block this axis in order
to attenuate EAE progression. Consistently it has been
reported that administration of the LXR agonist
T0901317 (which suppresses expression of IL-21 and
IL-22 mRNA) can inhibit EAE induction (Xu et al.
2009). Moreover, treatment of EAE mice with curcumin
could ameliorate disease (in part]) through the suppres-
sion of IL-21, IL-6, RORt and STAT3-mediated
signaling (Xie et al. 2009). Similarly, treatment of EAE
mice with IFN was associated with down-regulation of
IL-17, osteopontin and IL-21 (Chen et al. 2009).
Li et al. (2009) suggested that the expression of
epidermal fatty acid-binding protein (E-FABP) on T-
cells could enhance development of TH17 and suppress
that of Treg cells. Those investigators showed that the
myelin oligodendrocyte glycol-protein peptide (MOG)-
mediated induction of EAE in E-FABP-deficient mice
was associated with down-regulation of TH17 and up-
regulation of Treg cells, an outcome that was due in part
to significant decreases in IL-21 levels. It has also been
shown that tolerogenic DC can suppress EAE
Table 2. Studies related to the role of IL-21/IL-21R in EAE.
Main claim Reference
EAE
Diminished EAE disease progression in IL-21 KO mice, which was associated with the expansion of Treg cells Nurieva et al. (2007)
Administration of IL-21 before initiation of EAE enhanced autoimmune symptoms, which was associated with the
expansion of Treg and down-regulation of TH17 cells
Korn et al. (2007)
Treatment of EAE mice with salmonella-CFA/IIC greatly attenuated disease, in part through suppression of IL-17 and
IL-21
Ochoa-Reparaz et al. (2008)
Suppressed EAE by DNA vaccination through down-regulation of IL-21 Andersson et al. (2008)
Suppressed EAE induction via LXR agonist T0901317 through inhibition of IL-21 Xu et al. (2009)
Curcumin can attenuate EAE via inhibition of TH17 cells and IL-21 formation Xie et al. (2009)
Treatment of EAE mice with IFNb decreases IL-17 and IL-21 Chen et al. (2009)
Decreased TH17/IL-21 and increased Treg cells in E-FABP-deficient EAE mice Li et al. (2009)
Tolerogenic DC prevent EAE development via down-regulation of RORgt, IL-17A, IL-17F, IL-21 and IL-22 Zhou et al. (2014)
Salmon cartilage Proteoglycans reduce EAE progression via down-regulation of IL-6, IL-21, IL-23R and RORgt and up-
regulation of Foxp3
Sashinami et al. (2012)
Blockage of NR4A2 expression inhibits EAE through suppression of IL-21 production and IL-23R expression Raveney et al. (2013)
Aggravated EAE in BLIMP-1-deficient mice was associated with increased numbers of CNS-infiltrating TH1, TH17,
IFNg+IL-17A+ and IL-21+IL-17A+ CD4+ T-cells in brain and spinal cord.
Lin et al. (2014)
IL-21/IL-21R deficient mice are susceptible to EAE Coquet et al. (2008),
Sonderegger et al. (2008)
Inhibition of IL-21 was associated with increased entry of inflammatory cells into the CNS Piao et al. (2008)
Severe neurological impairment in IL-21R deficient EAE mice Piao et al. (2008), Liu et al. (2008)
Table 1. Studies related to expression of IL-21/IL-21R in MS patients.
Source of sample Outcome Reference
Peripheral blood Increased expression of IL-21 and IL-21R in CD4+ T cells from progressive MS Romme Christensen et al. (2013)
MS lesion (1) Increased expression of IL-21 only in infiltrating CD4+ cells in MS lesions
(2) IL-21R was broadly distributed on CD4+, CD19+ and CD8+ cells
Tzartos et al. (2011)
CSF Concentration of IL-21 in CSF of MS patients was not remarkably raised Wu et al. (2012)
DNA Association of IL-21R genetic polymorphisms with MS in Nordic population Nohra et al. (2010)
DNA No association of IL-21 gene with MS in Swedish population Linden et al. (2011)
DNA No association of TENR-IL-2-IL-21 locus on susceptibility or disease progression
in MS in Spanish population
Fedetz et al. (2009)
Serum No difference of IL-21 in MS patients compared to control subject Wang et al. (2011a)
Peripheral blood Increased expression of IL-21 mRNA during MS relapses Tegla et al. (2013)
CSF, Cerebrospinal Fluid; MS, multiple sclerosis; IL-21R, interleukin-21 receptor.
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development, in part through down-regulation of
RORt, IL-17A, IL-17F, IL-21 and IL-22 (Zhou et al.
2014). It has also been reported that treatment of EAE
mice with salmon cartilage proteoglycans could lead
to down-regulated IL-6, IL-21, IL-23R and RORt, and
up-regulated Foxp3 in both draining lymph nodes and
spinal cords (Sashinami et al. 2012).
NR4A2 (nuclear receptor sub-family 4, group A,
member 2) plays an important role in the differentiation
of TH17 cells and production of IL-21 and IL-17
cytokines. Consistently, in vivo inhibition of NR4A2
expression reduced TH17 and IL-21 levels and protected
mice against EAE induction (Raveney et al. 2013).
Moreover, it has been demonstrated that the frequencies
of CNS-infiltrating TH1, TH17, IFN
+IL-17A+ and IL-
21+IL-17A+ CD4+ T-cells were significantly increased in
the brain and spinal cord of B-lymphocyte-induced
maturation protein-1 (BLIMP-1)-deficient NOD mice
(Lin et al. 2014).
Contrary to the studies previously mentioned, there is
evidence to indicate the IL-21/IL-21R axis has no effect
on development of TH17 cells and that IL-21/IL-21R-
deficient mice are also susceptible to EAE progression
(Coquet et al. 2008; Sonderegger et al. 2008). Moreover,
increased infiltration of pro-inflammatory cells into the
CNS has also been seen when IL-21 was suppressed
(Piao et al. 2008). Another study showed the frequency
of Treg cells and expression of FoxP3 were significantly
decreased in both blocked IL-21 and IL-21R deficient
mice with EAE (Liu et al. 2008; Piao et al. 2008).
Interestingly, it was seen that IL-21R-deficient mice
developed EAE faster and in a more severe form when
compared to control mice. This faster initiation was also
associated with defective Treg and FoxP3 expression
and intact TH17 development. Moreover, recovery
among IL-21R-deficient mice was associated with
expansion of Treg cell levels and organ-specific redistri-
bution of NK cells (Liu et al. 2008).
Recent studies have shown that the new sub-sets of
B-cells that produce IL-10 can negatively regulate
immune responses; therefore, these cells are known as
regulatory B-cells (B10 or Breg cells) (Yanaba et al. 2008;
Yoshizaki et al. 2012). Generation of in vivo effector B10
cells depends on the presences of IL-21 and its receptor
(Tedder and Leonard 2014). Therefore, B10 cells regulate
immune responses by IL-10 production in neuro-
inflammatory processes such as MS (Tedder and
Leonard 2014). A study on purified spleen CD19+ B-
cells showed that IL-21 significantly increased the
production of IL-10 without the need of phorbol esters
and ionomycin for stimulation. The effector function of
B10 cells in EAE was dependent to the existence of
IL-21R, MHC-II and CD40 (Yanaba et al. 2009;
Yoshizaki et al. 2012). Moreover, initiation of EAE was
significantly reduced in mice treated by adoptive transfer
of antigen-specific (MOG-sensitized) B10 cells; it seems
this function was related to CD4+ T-cell IL-21 produc-
tion. Thus, it seems B10 cells could naturally regulate
acute immune responses in EAE in an IL-21-dependent
manner.
As noted earlier, there are conflicts between different
studies regarding the role of IL-21/IL-21R in the
immunopathogenesis of EAE (Table 2). However, these
discrepancies may be due to genetic backgrounds of
mice, different EAE-inducing protocols (using various
doses of antigen for EAE induction [i.e. 100mg (Bauquet
et al. 2009), 150 mg (Coquet et al. 2008) or 200 mg
(Vollmer et al. 2005)]) and the fact IL-21 is highly
pleiotropic – affecting many immune and non-immune
components of the body which have not been fully
addressed until recently (Spolski and Leonard 2014;
Croce et al. 2015). Further investigations with the same
disease induction protocols (in large scale) and optimal
doses of antigens are required to clarify the precise roles
for the IL-21/IL-21R axis in EAE.
Role of IL-21/IL-21R in immunopathogenesis
of MS
Since TH17 cells play an important role in the neuro-
inflammatory process of MS and IL-21 significantly
promotes the development of TH17, it seems that IL-21
may enhance MS progression. It has been reported that
simvastatin reduces neuro-inflammatory CNS lesion
formation in RR-MS patients (Giovannoni et al. 2014).
Zhang et al. (2011) reported that the mechanism by
which simvastatin exerted anti-inflammatory effects on
RR-MS patients was due in part to inhibition of TH17
and its secreted cytokines, particularly IL-21. Those
authors demonstrated that simvastatin blocked differen-
tiation of TH17 cells and generation of TH17-derived
cytokines (IL-17A, IL-17F, IL-21 and IL-22) in in vitro-
differentiated naive TH cells.
IL-21 not only inhibits the development of Treg cells
(Deenick and Tangye 2007; Petrelli et al. 2011), but also
converts Treg to TH17 (Yang et al. 2008) and increases
the resistance of conventional T-cells against the sup-
pressive function of Treg cells (Peluso et al. 2007).
Therefore, it seems that IL-21 enhances the development
of MS, in part, through the suppression of Treg cells. It
has been reported that treatment of MS patients with
UVB phototherapy was associated with down-regulation
of IL-21 and up-regulation of Treg cells and tolerogenic
DC, resulting in disease attenuation (Breuer et al. 2014).
It was also demonstrated that the frequency of TFH cells
was significantly increased in the peripheral blood and
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cerebrospinal fluid of RR-MS and SP-MS patients.
Moreover, increased expression of IL-21, IL-21R and
ICOS was noted in CD4+ T-cells obtained from
progressive MS patients. Treatment of such patients
with mitoxantrone was associated with the down-regu-
lation of TFH and IL-21, outcomes that led to disease
alleviation (Romme Christensen et al. 2013). Further,
accumulated populations of IL-21R+ and IL-21+CD4+
T-cells were observed in both active and chronic MS
lesions (Tzartos et al. 2011; Romme Christensen et al.
2013). Although most studies have shown that IL-21
indirectly plays an important role in the pathogenesis of
MS (Table 3), it is still necessary to conduct studies to
clarify the precise function of IL-21 in the pathogenesis
of the disease.
Alemtuzumab is a humanized monoclonal antibody
targeting the campath-1 antigen (CD52) that is broadly
expressed on immune cells. This antibody quickly
eliminates CD52-expressing immune cells from the
circulation. It has been suggested this antibody could
also exert neuroprotective effects, presumably by indu-
cing production of neurotrophic factors in autoreactive
T-cells (Klotz et al. 2012; Fernandez 2014). Alemtuzmab
can significantly reduce the rate of relapse in RR-MS
patients (Brown and Coles 2013). However, treatment of
MS patients with alemtuzumab may also be associated
with new secondary autoimmune disorders, such as
auto-immune thyroiditis or idiopathic thrombocytopae-
nic purpura (Jones et al. 2009; Klotz et al. 2012;
Fernandez 2014).
Treatment of MS patients with alemtuzumab also led
to decreased IL-21 levels (Zhang et al. 2013). Secondary
autoimmunity following treatment with alemtuzumab
usually occurs and can be predicted by the high baseline
levels of IL-21 in the MS sera (Costelloe et al. 2012).
Evaluation of IL-21 in the serum of MS patients prior to
treatment with alemtuzumab showed that groups of
patients who exhibited secondary autoimmunity had
higher levels of IL-21 compared to non-autoimmune
hosts (Jones et al. 2009; Costelloe et al. 2012). IFN has
usually been used as a first-line treatment for RR-MS
patients and can decrease production of IL-21 from
CD4+ T-cells (Tao et al. 2014). Thus, it would seem that
documented therapeutic effects of IFN are due in part
to a down-regulation of IL-21.
As discussed earlier, little is known regarding the
immunopathologic potential of IL-21/IL-21R in MS
patients. Thus, it is difficult to reach a conclusive result
based on previous studies about the precise role of IL-21/
IL-21R in the immune status of MS patients. With that
in mind, it appears IL-21 contributes to MS progression
partly through up-regulation of TH17 and down-regula-
tion of Treg cells. TH17 cells, which are the main
pathogenic cells in MS, produce IL-21 that can lead to
the expansion of the same and other TH17 cells in a
positive autocrine loop. Moreover, there is no compre-
hensive data regarding precise effects of IL-21 on other
immune cells involved in MS such as B-cells, macro-
phages/microglia and DC. Moreover, since IL-21 can
affect several immune and non-immune components of
the body, it is difficult to make a direct correlation
between the therapeutic mechanisms of some agents
and IL-21.
As discussed, there were several therapeutic agents
that could affect the production of different cytokines
(particularly IL-21) in the MS patients and EAE animal
models. It is not rational to assume, just because IL-21 is
included in affected cytokines, the major effect must
come from it rather than from a combination of
cytokines. Therefore, further comprehensive studies are
needed to discriminate the precise role of IL-21 in the
immunopathogenesis of MS between all affected
cytokines.
Conclusion
IL-21 affects the development and function of various
immune cells, including TH17, Treg, TFH, NK and B-cells.
Since these cells play an important role in the immune
responses, IL-21 may be involved in the immunopatho-
genesis of several diseases, such as MS (Figure 1).
Moreover, there is evidence supporting the theory that
IL-21 is in fact involved in the development of MS.
However, reports regarding the role of IL-21/IL-21R in
Table 3. Studies related to the role of IL-21/IL-21R in MS.
Main claim Reference
MS
Simvastatin exerts its anti-inflammatory effects in RR-MS patients, in part through inhibition of TH17 and IL-21 Zhang et al. (2011)
UVB phototherapy down-regulates IL-21 and up-regulates Treg and tolerogenic DC cell levels in MS patients Peluso et al. (2007)
Increased expression of IL-21, IL-21R and ICOS was observed in CD4+ T-cells from progressive MS patients.
Mitoxantrone decreased TFH and IL-21 in SP-MS patients
Romme Christensen et al. (2013)
Increased IL-21R+ and IL-21+CD4+ T-cells have been observed in the both active and chronic MS lesions Tzartos et al. (2011),
Romme Christensen et al. (2013)
Treatment of MS patients with alemtuzumab led to decreased IL-21 levels Zhang et al. (2013)
The secondary autoimmunity following treatment with alemtuzumab can be predicted via high baseline
levels of IL-21 in MS sera
Costelloe et al. (2012), Jones et al. (2009)
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EAE animal models remain controversial. One item
that needs to be clarified is the role of IL-21 in the
development and function of B10 cells in EAE and MS.
This issue will determine whether IL-21 can be con-
sidered as having a protective role in MS or not. On the
other hand, little is known regarding the precise role of
the cytokine in the immunopathogenesis of MS. As IL-21
promotes development of effector cells involved in the
neuro-inflammatory process associated with MS such as
TH17 and directly inhibits induction of Treg cells,
therefore inhibition of IL-21 may be considered a
worthy target for MS therapy. However, it should be
noted that Treg and TH17 cells are in the reciprocal
regulation and development of each cell is associated
with expansion of another one. Further investigations
regarding the immunobiology of IL-21 are required to
enable the designing of novel therapeutics based on
IL-21 targeting.
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